Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes mortality at maximal compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes cancer‐related mortality at maximal compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of participants) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of events) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
Percutaneous alcohol injection may leads to higher cancer‐related mortality at maximal compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Overall survival · women treated for early breast cancer
Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).
1 finding from 1 review
Disease-free survival · women treated for early breast cancer
Summary of findings: Non‐intensive showed no clear difference in disease‐free survival compared with intensive follow‐up (low certainty).
1 finding from 1 review
Quality of life4 · women treated for early breast cancer
1 finding from 1 review
Overall survival · women treated for early breast cancer
Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).
1 finding from 1 review
Disease-free survival · women treated for early breast cancer
Summary of findings: Decentralised showed no clear difference in disease‐free survival compared with centralised follow‐up (moderate certainty).
1 finding from 1 review
Quality of life5 · women treated for early breast cancer
1 finding from 1 review
Overall survival at 5‐year · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review